Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
1.270
-0.090 (-6.62%)
At close: Apr 10, 2026, 4:00 PM EDT
1.370
+0.100 (7.87%)
After-hours: Apr 10, 2026, 7:22 PM EDT
Celularity Revenue
Celularity had revenue of $5.28M in the quarter ending September 30, 2025, a decrease of -43.16%. This brings the company's revenue in the last twelve months to $40.58M, down -15.81% year-over-year. In the year 2024, Celularity had annual revenue of $54.22M with 138.11% growth.
Revenue (ttm)
$40.58M
Revenue Growth
-15.81%
P/S Ratio
0.90
Revenue / Employee
$329,902
Employees
123
Market Cap
36.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.22M | 31.45M | 138.11% |
| Dec 31, 2023 | 22.77M | 4.80M | 26.68% |
| Dec 31, 2022 | 17.98M | -3.36M | -15.75% |
| Dec 31, 2021 | 21.34M | 7.06M | 49.43% |
| Dec 31, 2020 | 14.28M | -6.87M | -32.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 120.77M |
| Cue Biopharma | 27.47M |
| Veru Inc. | 16.89M |
| Immutep | 5.28M |
| CervoMed | 4.01M |
| Werewolf Therapeutics | 1.14M |
| Hyperion DeFi | 813.46K |
CELU News
- 4 weeks ago - Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - GlobeNewsWire
- 4 weeks ago - EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue - Benzinga
- 4 weeks ago - Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy - GlobeNewsWire
- 2 months ago - Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses - GlobeNewsWire
- 3 months ago - Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations - GlobeNewsWire
- 3 months ago - Celularity Announces Closing of Financing Transactions - GlobeNewsWire
- 4 months ago - Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision - GlobeNewsWire
- 5 months ago - Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care - GlobeNewsWire